ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

AbbVie

Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.

AbbVie Cuts Its Guidance on ImmunoGen Deal

AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal.

AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$11.25 which now includes a $0.42 per share dilutive impact related to the ImmunoGen acquisition and the pending Cerevel Therapeutics acquisition AbbVie updates previously issued 2024 first-quarter adjusted diluted EPS guidance range from $2.30-$2.34 to $2.26-$2.30 which now includes a $0.04 per share dilutive impact related to the ImmunoGen acquisition NORTH CHICAGO, Ill. , Feb. 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).

AbbVie Completes Acquisition of ImmunoGen

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

ACM Research

Celsius Holdings

Crocs

Fluor

Immunovant Inc

Uranium Energy

As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.

How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry

Amgen

AstraZeneca

Bristol-Myers

Cerevel Therapeutics Holdings Inc

Horizon Pharma

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy

GitLab

IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.

Best Momentum Stocks to Buy for January 4th

BlackLine

Finward Bancorp

Taylor Morrison Home

IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.

New Strong Buy Stocks for January 4th

AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

Amphastar Pharma

Neurocrine Biosciences

Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments, not only to attack important diseases but also to prevent them.

3 Stocks at the Forefront of Medical Innovation

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Findings from Newly Diagnosed AML Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Azacitidine and Venetoclax at ASH.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Coupang

Certain smart money stocks catch the discerning eye of big players in investing, drawing in substantial investments. Delving into the strategies and growth patterns of three companies reveals intriguing insights into why these companies have piqued the interest of notable investors.

Market Movers: Why Big Players Are Investing Millions in These 3 Stocks

U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals to support its growth.

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

Duolingo

Sprouts Farmers Markets

Small-cap stocks are a good option for investors looking to gain exposure to typically newer companies offering niche products and services that may have the potential for massive share price appreciation. But, these companies are also risky because they are more susceptible to collapse from financial instability, mismanagement and an economic downturn.

Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch

The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologics License Application (sBLA) supporting the conversion of the accelerated approval of ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian,.

FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ImmunoGen, Inc. (NasdaqGS: IMGN) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of ImmunoGen will receive $31.26 in cash for each share of ImmunoGen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet.

IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN

Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice

From a technical perspective, ImmunoGen (IMGN) is looking like an interesting pick, as it just reached a key level of support. IMGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

ImmunoGen (IMGN) Just Flashed Golden Cross Signal: Do You Buy?

AbbVie has announced its acquisition of ImmunoGen for $10.1 billion in cash, marking a strategic move amidst rising competition for their leading treatment, Humira. ImmunoGen's Elahere, part of the innovative class of antibody-drug conjugates (ADC), specifically targets cancer cells, offering potential benefits in reducing toxicity for surrounding cells.

AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

News for ImmunoGen Stock (IMGN)